

18-19 November 2016 • Barcelona, Spain

PrEP 2016: Nurses' Role in Scaling Up PrEP Access within a Combination HIV Prevention Approach

Nathaniel Brito-Ault Barts NHS Trust, London, England

Benjamin Young International Association of Providers of AIDS Care Washington DC, USA



Objectives

- Describe clinical indications for PrEP
- Apply findings from current research to PrEP implementation and adherence
- Appreciate lessons learned from PrEP implementation in US, France and England







Recommendation

Oral pre-exposure prophylaxis (PrEP) containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches (strong recommendation, high-quality evidence).

Source: Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (http://www.who.int/hiv/pub/guidelines/earlyrelease-anv/en).



Defining risk (CDC): Men who have sex with men

BOX B1: RECOMMENDED INDICATIONS FOR PREP USE BY MSM²

- Adult man
- Without acute or established HIV infection
- Any male sex partners in past 6 months (if also has sex with women, see Box B2)
- Not in a monogamous partnership with a recently tested, HIV-negative man

AND at least one of the following

- Any anal sex without condoms (receptive or insertive) in past 6 months
- Any STI diagnosed or reported in past 6 months
- Is in an ongoing sexual relationship with an HIV-positive male partner



Defining risk (CDC): Heterosexuals

BOX B2: RECOMMENDED INDICATIONS FOR PREP USE BY HETEROSEXUALLY ACTIVE MEN AND WOMEN

- Adult person
- Without acute or established HIV infection
- Any sex with opposite sex partners in past 6 months
- Not in a monogamous partnership with a recently tested HIV-negative partner

AND at least one of the following

- Is a man who has sex with both women and men (behaviorally bisexual) [also evaluate indications for PrEP use by Box B1 criteria]
- Infrequently uses condoms during sex with 1 or more partners of unknown HIV status who are known to be at substantial risk of HIV infection (IDU or bisexual male partner)
- Is in an ongoing sexual relationship with an HIV-positive partner



EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain

Defining risk (CDC): People who inject drugs

BOX B3: RECOMMENDED INDICATIONS FOR PREP USE BY INJECTION DRUG USERS

- Adult person
- Without acute or established HIV infection
- Any injection of drugs not prescribed by a clinician in past 6 months

AND at least one of the following

- Any sharing of injection or drug preparation equipment in past 6 months
- Been in a methadone, buprenorphine, or suboxone treatment program in past 6 months
- Risk of sexual acquisition (also evaluate by criteria in Box B1 or B2)




Clinical Trial Evidence for Oral and Topical TDF-Based Prevention

Serodiscordan couples	nt (Discordant couples—Kenya, Uganda) Partners PrEP—daily oral tenofovir (Discordant couples—Kenya, Uganda)			75% (55-87) 67% (44-81)	
(M	iPrEx—daily oral TDF/FTC ISM—North and South America, Thailand, South Africa)		—	44% (15-63)	
MSM	PROUD—daily TDF/FTC (MSM—UK)			86% (58-96) (90% CI)	
	IPERGAY—intermittent TDF/FTC (MSM—France, Canada)			-86% (40-98)	
Heterosexual men and wom	TDF2—daily TDF/FTC en (Heterosexual men and women—Botswana)		—	62% (22-84)	
Heterosexual women	CAPRISA 004—"BAT-24" dosing vaginal TDF gel (Women—South Africa)		—	39% (6-60)	
	FACTS 001—"BAT 24" dosing vaginal TDF gel (Women—South Africa)	•		0% (-1 to 2)	
	MTN 003/VOICE—daily vaginal dosing tenofovir gel (Women—South Africa, Uganda, Zimbabwe)		—	15% (-21 to 40)	
	FEM-PrEP—daily oral TDF/FTC (Women—Kenya, South Africa, Tanzania)		•	6% (-52 to 41)	
	MTN 003/VOICE—daily oral TDF/FTC (Women—South Africa, Uganda, Zimbabwe)	•		-4% (-49 to 27)	
	MTN 003/VOICE—daily oral tenofovir (Women—South Africa, Uganda, Zimbabwe)	•	-	-49% (-129 to 3)	
People who inject drugs	Bangkok TDF study—daily oral TDF (IDUs—Thailand)		•	49% (10-72)	
	-130	-60 -40 -20 (0 20 40 60 80	100	
	Effectiveness (%)				
2	H, et al. Curr Opin HIV AIDS. 2015;10:2	226-232.			

Modified from AVAC Report. 2013.

Slide credit: clinicaloptions.com

PrEP Is Well Tolerated; Discontinuations due to Adverse Events Are Rare



- No difference in proportion of participants reporting any AE (RR: 1.01; 95% CI: 0.99-1.03, P = .27) or any grade 3/4 AE in PrEP vs placebo arms
- Several studies noted subclinical declines in renal functioning and BMD among PrEP users

WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.


Slide credit: <u>clinicaloptions.com</u>

iPrEX: Bone Mineral Density Substudy

- iPrEX substudy: dual-energy x-ray absorptiometry assessment (N = 498)
- Small net decrease in spine and total hip BMD with TDF/FTC vs PBO at Wk 24 (-0.91% and -0.61%, respectively; P = .001 for both)
- No difference in fracture rate between groups (P = .62)

Mulligan K, et al. Clin Infect Dis. 2015;61:572-580.

Mean Net Treatment Difference in BMD Change, Placebo – TDF/FTC (95% CI)




Slide credit: clinicaloptions.com

do

iPrEx BMD Substudy: BMD Recovery After Discontinuation of TDF/FTC PrEP

■ Data compared for TFV-DP < or ≥ 16 fmol/M viable PBMC, concentration associated with 90% reduction in HIV infection risk in MSM/TGW</p>




Cumulative TFV/FTC Exposure During PrEP Assoc. With Decline in Renal Fxn

- Higher TFV exposure associated with greater eGFR decreases in 2 studies
 - iPrEx OLE^[1] (n = 220): hair sampling for exposure
 - US Demo Project^[2] (n = 557): dried blood spot sampling for exposure
- In both studies, eGFR decrease to < 70 mL/min more frequent among those with BL eGFR < 90 mL/min and older persons (older than 40-45 yrs)

Gandhi M, et al. CROI 2016. Abstract 866.
 Liu AY, et al. CROI 2016. Abstract 867.


Change in eGFR From BL vs Concentration of TFV or FTC in Hair^[1]



PROUD: Immediate vs Deferred PrEP in High-Risk MSM in "Real World" Trial

- Randomized, open-label trial of daily oral TDF/FTC PrEP in uninfected MSM at high risk for HIV infection in England
 - PrEP: immediate vs deferred for 12 mos
- Fewer new HIV infections with immediate vs deferred PrEP (3 vs 20)
 - Number needed to treat to prevent 1 infection: 13
- PEP used by 32% in deferred arm
- Risk behaviors similar between arms

McCormack S, et al. Lancet. 2016;387:53-60.



Slide credit: clinicaloptions.com

Bangkok Tenofovir Study: PrEP Efficacy in IDUs

 HIV-negative adults aged 20-60 yrs reporting IDU in previous yr randomized to PrEP with TDF QD (n = 1204) or PBO (n = 1209); pts could choose DOT or monthly visits

Kaplan-Meier Estimates of Time to HIV Infection in Modified ITT Population 10 -Cumulative Probability of HIV Infection (%) 8 Tenofovir Placebo 6. 4 2 0 12 36 72 24 48 60 84 $\mathbf{0}$ **Mos Since Randomization**

 Risk of infection significantly decreased with TDF PrEP (48.9%; P = .01)

 For pts who became infected and met adherence criteria (took study drug > 71% of days with < 2 consecutive days off study drug, n = 17), TDF PrEP reduced risk of infection 55.9% (-18.8% to 86.0%; P = 0.11)


 In pts with detectable TDF: 73.5% (16.6% to 94.0%; *P* = .03)

Choopanya K, et al. Lancet. 2013;381:2083-2090.

Slide credit: clinicaloptions.com

Effectiveness and Adherence in Trials of Oral and Topical TDF-Based Prevention

Effectiveness and Adherence in Trials of Oral and Topical TDF-Based Prevention




- Higher adherence associated with greater protection
 - Slide credit: clinicaloptions.com

AVAC Report. 2013.

iPrEX OLE: PrEP Reduces Incidence of HIV Even With Incomplete Adherence

- Open-label extension of iPrEX trial; N = 1603 (75% receiving PrEP)
- 100% adherence was not required to attain full benefit from PrEP
 - Benefit of 4-6 tablets/wk similar to 7 tablets/wk
 - 2-3 tablets/wk also associated with significant risk reduction
- Higher levels of sexual risk taking at baseline associated with greater adherence to PrEP


Grant R, et al. IAC 2014. Abstract TUAC0105LB. Grant R, et al. Lancet Infect Dis. 2014;14:820-829.



Slide credit: <u>clinicaloptions.com</u>

PrEP Demonstration: High Adherence in STD/Community-Based Clinics

- Prospective, open-label study of 48 wks of daily oral TDF/FTC PrEP for MSM/TGW (N = 557)
 - 3 US STD or community-based clinics in San Francisco, Miami, and Washington, DC
- Of pts with at least 2 DBS tested (n = 272), 62.5% had protective TFV levels (consistent with ≥ 4 doses/wk) at all visits
 - 3% had TFV levels consistent with < 2 doses/wk
- PrEP dispensation interrupted in 15%: most commonly due to AE concerns or low perceived risk
- Overall STI incidence remained stable during follow-up (90/100 PY)




Liu AY, et al. JAMA Intern Med. 2016;176:75-84.

Slide credit: clinicaloptions.com

Practical Considerations for PrEP



PrEP Alone Is Not Sufficient



STI Screening and Incidence During PrEP

- Analysis of STI occurrence in pts in SPARK, a PrEP demonstration project at a NY health care center^[1]
 - Pts screened for STIs every 3 mos while receiving PrEP; also visited clinic if experienced symptoms
 - CDC PrEP guidelines suggest STI screening every 6 mos^[2]

Time Point	Ν	STI Diagnosis, n (%)	Diagnosed by Routine Screening, n (% STIs)	Repeat STIs, n (% STIs)
6 mos before PrEP	280	35 (13)	NA	NA
PrEP prescription	280	31 (11)	31 (100)	8 (26)
3-mo follow-up	225	30 (13)	23 (77)	10 (33)
6-mo follow-up	196	41 (21)	34 (83)	20 (48)
9-mo follow-up	169	25 (15)	17 (68)	21 (84)
12-mo follow-up	128	17 (13)	13 (77)	13 (77)

- At all time points, majority of pts (> 71%) had rectal STIs
- Golub S, et al. CROI 2016. Abstract 869.
 CDC. PrEP Guidelines. 2014.

Slide credit: <u>clinicaloptions.com</u>

PrEP is not foolproof, even with optimal adherence.





I MINKSTOCK

TREATMENT NEWS

PrEP Fails in Gay Man Adhering to Daily Truvada, He Contracts Drug-Resistant HIV

February 25, 2016 . By Benjamin Ryan



EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain





TREATMENT NEWS

Second Man Contracts Rare HIV Strain While Adhering to PrEP

But such cases are likely to remain very uncommon.

October 19, 2016 . By Benjamin Ryan






EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain

PrEPWatch.org

US TDF/FTC PrEP Use From 2012-2015

- Analysis of TDF/FTC PrEP prescription data from 2012-2015 in US retail pharmacies
- PrEP initiation increased 738% from 2012-2015

Persons Initiating TDF/FTC PrEP, 2012-2015 (N = 79,684)



- Women comprised 44% of individuals starting PrEP in 2012 vs 17% in 2015
- Mean age of those initiating PrEP in 2015: 36.2 yrs


Mera R, et al. IAC 2016. Abstract TUAX0105LB.

Slide credit: <u>clinicaloptions.com</u>

PrEP Implementation in France in 2016

Cumulative No.

- > 90 PrEP clinics have opened, initially in ANRS Ipergay sites (Paris, Lyon, Nice, Lille, Nantes)
- **AIDES** Website: http://www.aides.org/infosante/prep
- **TDF/FTC** can be prescribed by 600 hospital-based HIV specialists and STI clinics since June 2016 400
- **TDF/FTC** can be obtained at private and hospital pharmacies





PrEP Use and HIV/STI Incidence Clinical Practice (San Francisco)

- Analysis of PrEP use and HIV/STI incidence in PrEP users in large healthcare system (Kaiser Permanente San Francisco) from 2012 to 2015
 - 1045 referrals for PrEP; 801 individuals with ≥ 1 intake visit
 - 657 initiated PrEP (82%*); mean duration of use 7.2 mos
- Key results (PrEP initators):
 - No HIV diagnoses (388 PY follow-up)
 - After 12 months, 50% diagnosed with any STI
 - 33% rectal STI; 33% chlamydia; 28% gonorrhea
 - After 6 mos PrEP, self-reported condom use was decreased in 41% of individuals



PrEP Implementation: Denver

APEX Family Medicine

- Largest private HIV treatment and PrEP provider in region
- General/Family Practice providers
 - 3 physicians
 - 4 nurse practitioner/physician assistant
- 1000 HIV+ patients, 500 on
 PrEP
- No HIV seroconversion among
 PrEP patients in 2 years





EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain

Online PrEP Purchase: London

- 56 Dean Street Clinic, London
- 191/208 patients purchased PrEP online
 - Most was Cipla Tenvir-EM
 - _ £1.68/pill (vs £11.86 in BNF)
- Drug testing found adequate levels
- No cases of HIV seroconversion
- Kidney function normal

Nwokolo, HIV Glasgow 2016



EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain

Lessons Learned: France

- Close partnership with the community and strong political support have led to PrEP approval
- Increase PrEP awareness among doctors and people at risk (MSM, transgender, and heterosexual migrants)
- Adapt available resources to provide comprehensive sexual health care and meet the demand
- Define best models of care and access points (hospitals, sexual health clinics, GP)
- High risk people self-select for PrEP: HIV-infection detected at

screening or soon after PrEP initiation




Challenges with PrEP Roll-Out:France

- Dedicated nurses to provide information/appointment by email and tel
- Organize outpatient clinic to meet the demand
 - Inform nurses and administrative personnel
 - Identify doctors willing to provide PrEP (> 10 doctors)
 - Increase offer: 10 consultations per week (2 to 3 from 6-10 pm)
- PrEP can be started <u>at first visit</u> and patients seen at Month 1 and every 3 months
- Adapt outpatient clinic for STI treatment (injections)
- Peer-counseling (PrEP adherence, risk reduction)



New England Prescribers Perceived Numerous Barriers to Prescribing PrEP

Clinician Perceived Barriers to Prescribing PrEP (N = 155)



Time constraints (eg, to discuss PrEP,

Concerns about whether insurers will

Limited number of high-risk, HIV-uninfected pts

Clinicians not aware of guidance from

Clinicians not trained to prescribe PrEP

Minor barrier Moderate barrier

- Major barrier

Not a barrier

Numbers within bars represent the percentage of participants selecting each response category.

CO

Krakower DS, et al. PLoS One. 2015;10:e0132398.

Slide credit: clinicaloptions.com

Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings

Julia L. Marcus¹ · Jonathan E. Volk² · Jess Pinder³ · Albert Y. Liu⁴ · Oliver Bacon⁴ · C. Bradley Hare² · Stephanie E. Cohen⁴

- PrEP programs in health maintenance organization, STD clinic and primary care practice.
- PrEP reaching high-risk populations, but gaps exist (minority/adolescent MSM, PWID, TG)
- Building capacity among primary care providers to take sexual history needed.
- Self-collection for STI screening may reduce burden healthcare system

- Train non-physician providers to administer aspects of PrEP care.
- More frequent STI testing in some settings.
- Cost continues to be a barrier for some.
- Engagement of public health departments can support PrEP implementation

EUROPEAN HIV NURSING CONFERENCE 18-19 November 2016 • Barcelona, Spain Curr HIV/AIDS Rep (2016) 13:116-124

Take-home points

- PrEP works, and access is improving (if slowly) in Europe
 - Where not available, people are accessing PrEP privately or via internet
- Clinic/laboratory monitoring critical (HIV, HBV, renal, bone)
- PrEP is an important component of comprehensive sexual healthcare
- Nurses can aid in PrEP advocacy, access and service delivery
- Addressing barriers to care and appropriate task shifting are key to effective PrEP implementation



Thank you! Gracies!



APEX Family Medicine, Denver

Mia Scott, DO; Michael Mohr DO; Lorraine Van Slyke NP; Allison Russell PA; Derek Miller PA; Barb Widick, RN; Amy Thomas; Billie Thomas

byoung@iapac.org

